Fiche centre
University of California, Davis
Sacramento — United States
Essais liés8clinical trials
VilleSacramentolocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06138639
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| [18F]DPA-714 Positron Emission Tomography Scan | Épilepsie | Phase 1 | NCT03999164 | Imaging of Neuro-Inflammation and the Risk for Post-Traumatic Epilepsy | ACTIVE_NOT_RECRUITING |
| Placement of the BrainGate2 sensor(s) into the motor-related cortex | Myopathies | Non applicable | NCT00912041 | BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia | RECRUITING |
| Deramiocel (CAP-1002) | Myopathies | Phase 3 | NCT05126758 | HOPE-3 — A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING |
| SAA — Serum Auto-Antibodies in Neurological Diseases | Myasthénie | À vérifier | NCT00704626 | SAA — Serum Auto-Antibodies in Neurological Diseases | ENROLLING_BY_INVITATION |
| CNP-106 | Myasthénie | Phase 1/2 | NCT06106672 | Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| delandistrogene moxeparvovec | Myopathies | Phase 1 | NCT04626674 | ENDEAVOR — A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort | RECRUITING |
| SGT-003 | Myopathies | Phase 1/2 | NCT06138639 | A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | RECRUITING |
| Vamorolone | Myopathies | À vérifier | NCT06564974 | DMD-001 SUMMIT — Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT | RECRUITING |